Preventive effect of rebamipide on chemotherapy-induced oral mucositis in cancer patients

Preventive effect of rebamipide on chemotherapy-induced oral mucositis in cancer patients - Preventive effect of rebamipide on oral mucositis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004765

Enrollment

Registered

2010-12-22

Start date

2008-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oral mucositis

Interventions

no treatment treatment 1 with rebamipide treatment 2 with rebamipide treatment 3 with rebamipide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Cancer patients who will be treated with chemotherapy 2. Patients who can take rebamipide 3. Patients with written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients treated with rebamipide 2. Patients with oral mucositis 3. Patients who will be treated with radiation on head and neck within the study period 4. Patients with allergy history for rebamipide

Design outcomes

Primary

Measure	Time frame
incidence of oral mucositis	—

Countries

Japan

Contacts

Public ContactKohji Naora

Shimane University Hospital Department of Pharmacy

knaora@med.shimane-u.ac.jp0853-23-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026